DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy.
Summary
This phase II study investigated the efficacy and safety of durvalumab plus olaparib as maintenance therapy in 60 previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients. The combination regimen demonstrated promising efficacy, with a 12-month progression-free survival rate of 25.0%, a median progression-free survival of 6.8 months, and a median overall survival of 14.6 months. Multi-omics analysis identified a DNA hypomethylation subgroup associated with significantly improved survival outcomes. This subgroup exhibited enhanced antigen presentation, a favorable cytokine profile, and suppressed DNA damage repair pathways, suggesting a potential biomarker for patient selection.
Analysis
CLINIQUE: This single-arm, multicenter phase II study provides the first prospective evidence supporting durvalumab plus olaparib as maintenance therapy for extensive-stage small-cell lung cancer. The promising efficacy results, including a median PFS of 6.8 months and a median OS of 14.6 months, are significant for a disease with historically poor long-term survival. The identification of a DNA hypomethylation subgroup, associated with significantly improved survival outcomes, is a critical finding. This hypomethylation status could serve as a predictive biomarker to select patients most likely to benefit from this combination, potentially justifying phase III trials to validate this approach and change clinical practice in the medium term (3-5 years). BIOMOL: The multi-omics analysis led to the discovery of a SCLC patient subgroup characterized by DNA hypomethylation, which showed enhanced response to the durvalumab and olaparib combination. This molecular phenotype is linked to enhanced antigen presentation machinery, a favorable cytokine profile, and suppression of DNA damage repair (DDR) pathways, potentially through elevated promoter methylation and transcriptional silencing of specific DDR genes. This mechanistic discovery is highly translational, as it identifies a sensitivity mechanism to PARP inhibitors and immunotherapy, and proposes an epigenetic biomarker (DNA hypomethylation status) that could be validated in future clinical tests to stratify patients. BIOINFO: The multi-omics approach was instrumental in characterizing molecular subtypes associated with clinical outcomes. While specific algorithms are not detailed, the integration of data from various platforms (genomics, epigenomics, transcriptomics) allowed for the identification of an epigenetic biomarker (DNA hypomethylation) with strong predictive value. This application of bioinformatics for patient stratification exemplifies its potential to refine precision medicine by identifying complex molecular signatures that would not be apparent from a single data modality.